Abstract
Background
Hypoglycemia is extremely uncommon as the first presentation of hepatocellular carcinoma, and it occurs predominantly as a paraneoplastic manifestation.
Methods
We report a case of a 38-year-old-man positive for hepatitis B surface antigen with high-serum viremia who presented with symptoms of acute severe hypoglycemia.
Results
Laboratory tests confirmed hypoglycemia (serum glucose 1.54 mmol/L) with undetectable serum-C peptide (<0.5 µIU/mL) and slightly increased serum insulin concentration (35 µIU/mL). Alpha-fetoprotein serum level was 75,625 ng/mL. Abdominal ultrasonography and computed tomography revealed a big vascularized mass of 13 cm in diameter occupying most of the right lobe of the liver and an 18F-fluoro-2-deoxy-D-glucose positron-emission tomography revealed a predominant uptake of glucose by the tumor mass.
Conclusions
These findings indicate that hepatocellular carcinoma-associated hypoglycemia may be due exclusively to increased glucose utilization by the tumor mass.
References
World Health Organization. (2008). Mortality database. Available from: http://www.who.int/whosis/en
Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13–20.
Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143–54.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
Ross JS, Kurian S. Clear cell hepatocellular carcinoma: sudden death from severe hypoglycemia. Am J Gastroenterol. 1985;80:188–94.
Ndububa DA, Ojo OS, Adetiloye VA, Rotimi O, Durosinmi MA, Uchegbu LO. The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. Eur J Gastroenterol Hepatol. 1999;11:1401–4.
Chu CW, Hwang SJ, Luo JC, Tsay SH, Li CP, Chang FY, et al. Manifestation of hypercholesterolaemia, hypoglycemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. J Gastroenterol Hepatol. 1999;14:807–10.
Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology. 2002;49:1315–9.
Saigal S, Nandeesh HP, Malhotra V, Sarin SK. A case of hepatocellular carcinoma associated with troublesome hypoglycemia: management by cytoreduction using percutaneous ethanol injection. Am J Gastroenterol. 1998;93:1380–1.
Nikeghbalian S, Bananzadeh A, Yarmoammadi H. Hypoglycemia, the first presenting sign of hepatocellular carcinoma. Saudi Med J. 2006;27:387–8.
McFadzean AJ, Yeung RTT. Hypoglycemia in primary carcinoma of the liver. Arch Intern Med. 1956;98:720–31.
McFadzean AJ, Yeung RTT. Further observations on hypoglycemia in hepatocellular carcinoma. Am J Med. 1969;47:220–35.
Yeung RTT. Hypoglycemia in hepatocellular carcinoma: a review. HKMJ. 1997;3:297–301.
Shapiro ET, Bell GI, Polonsky KS, Rubenstein AH, Kew MC, Tager HS. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor II. J Clin Invest. 1990;85:1672–9.
Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, et al. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest. 1992;89:1958–63.
Yonei Y, Tanaka M, Ozawa Y, Miyazaki K, Tsukada N, Inada S, et al. Primary hepatocellular carcinoma with severe hypoglycemia; involvement of insulin-like growth factors. Liver. 1992;12:90–3.
Yamaguchi M, Kamimura S, Takada J, Iwata K, Iida T, Kobayashi K, et al. Case report: insulin-like growth factors II expression in hepatocellular carcinoma with alcoholic liver fibrosis accompanied by hypoglycemia. J Gastroenterol Hepatol. 1998;13:47–51.
Ishida S, Noda M, Kuzuya N, Kubo F, Yamada S, Yamanaka T, et al. Big insulin-like growth factor II- producing hepatocellular carcinoma associated with hypoglicemia. Intern Med. 1995;34:1201–6.
Kahn CR. The riddle of tumor hypoglycemia revisited. Clin Endocrinol Metabol. 1980;95:505–17.
Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319:1434–40.
Thorgeirsson SS, Grishman JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.
Aihara T, Noguchi S, Miyoshi Y, Nakano H, Sasaki Y, Nakamura Y, et al. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology. 1998;28:86–9.
August JT, Hiatt HH. Severe hypoglycemia secondary to a nonpancreatic fibrosarcoma with insulin activity. N Engl J Med. 1958;258:17–20.
Perkoff GT, Simons EL. Hypoglycemia in a patient with a fibrous tumor. Arch Intern Med. 1963;112:589–93.
Chowdhury F, Bleicher SJ. Studies of tumor hypglycemia. Metab Clin Exp. 1973;22:663–74.
Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomised rats. J Clin Invest. 1986;77:1768–75.
Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology. 1995;21:680–8.
Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54:1170.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sorlini, M., Benini, F., Cravarezza, P. et al. Hypoglycemia, an Atypical Early Sign of Hepatocellular Carcinoma. J Gastrointest Canc 41, 209–211 (2010). https://doi.org/10.1007/s12029-010-9137-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-010-9137-0